Montelukast%25252525252525252525252520levocetrizine

# Montelukast / Levocetirizine ## Overview This combination is often prescribed off-label for the management of chronic allergic conditions, specifically chronic urticaria or allergic rhinitis. Montelukast is a selective leukotriene receptor antagonist, while levocetirizine is a potent, third-generation H1-receptor antagonist. ## Primary Indications - Chronic idiopathic urticaria - Allergic rhinitis (when monotherapy is insufficient) ## Adult Dosing - **Montelukast:** 10 mg orally once daily in the evening. - **Levocetirizine:** 5 mg orally once daily in the evening. ## Pediatric Dosing - **Ages 6 to 14 years:** - Montelukast: 5 mg (chewable) orally daily. - Levocetirizine: 2.5 mg orally daily. - **Ages 2 to 5 years:** - Montelukast: 4 mg (chewable or oral granules) orally daily. - Levocetirizine: 1.25 mg orally daily. *Note: Use caution in patients under 2 years; efficacy/safety data is limited for this combination.* ## Dose Adjustments - **Renal Impairment (Levocetirizine):** Requires adjustment based on creatinine clearance (CrCl). If CrCl 30–49 mL/min, 2.5 mg every 48 hours; if CrCl 10–29 mL/min, 2.5 mg twice weekly. Avoid in end-stage renal disease (CrCl <10 mL/min). - **Hepatic Impairment:** No adjustment for Montelukast, but monitor closely. ## Contraindications - Hypersensitivity to montelukast, levocetirizine, or cetirizine. - End-stage renal disease or hemodialysis (levocetirizine). ## Adverse Effects - **Montelukast:** Neuropsychiatric events (agitation, aggression, depression, suicidal ideation), headache, upper respiratory infection. - **Levocetirizine:** Somnolence, fatigue, nasopharyngitis, xerostomia (dry mouth). ## Key Drug Interactions - **CYP2C8/2C9/3A4 Inducers (e.g., Rifampin, Phenytoin):** May decrease montelukast plasma concentrations. - **CNS Depressants:** Concomitant use with alcohol or sedatives may enhance the sedative effects of levocetirizine. - **Ritonavir:** May increase plasma concentrations of levocetirizine. ## Monitoring - Monitor for the emergence of neuropsychiatric symptoms (mood changes, behavioral changes, sleep disturbances). - Monitor renal function in patients with pre-existing renal impairment. - Assess for efficacy in symptom control after 2–4 weeks; discontinue if no improvement. ## Clinical Pearls - **FDA Boxed Warning (Montelukast):** The FDA requires a bolded warning regarding serious neuropsychiatric events. Providers should weigh risks vs. benefits and advise patients to stop the medication immediately if behavioral changes occur. - **Evening Dosing:** Both are typically administered in the evening to counteract symptom flares that often occur in the early morning and to manage the sedative side effects of the antihistamine. - **Off-Label Status:** This combination is not an FDA-approved fixed-dose combination product. Doses are typically calculated based on individual components. *** **Educational Disclaimer:** This information is for educational purposes only. Always verify dosages, contraindications, and drug interactions using current clinical resources (e.g., Lexicomp, Micromedex, or the official FDA package insert) prior to prescribing or administration. Individual patient factors must be considered.